A Phase 2/3, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
September 11, 2026
A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors